{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:40:46Z","timestamp":1764175246431},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,12]]},"DOI":"10.7759\/cureus.24952","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T04:11:06Z","timestamp":1652415066000},"source":"Crossref","is-referenced-by-count":3,"title":["Acute Onset of Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Two Weeks After COVID-19 Vaccination With mRNA-1273 With Possible Activation of Parvovirus B19: A Case Report With Literature Review"],"prefix":"10.7759","author":[{"given":"Hiroto","family":"Arino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokazu","family":"Muramae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsumasa","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Otsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai L","year":"2021","unstructured":"Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021, 21:73-82. 10.1038\/s41577-020-00480-0","journal-title":"Nat Rev Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet T","year":"2022","unstructured":"Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022, 28:202-21. 10.1016\/j.cmi.2021.10.005","journal-title":"Clin Microbiol Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson LA","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, et al.. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020, 383:1920-31. 10.1056\/NEJMoa2022483","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2113864","article-title":"BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant","volume":"385","author":"Sheikh A","year":"2021","unstructured":"Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant. N Engl J Med. 2021, 385:2195-7. 10.1056\/NEJMc2113864","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03360190069027","article-title":"Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome","volume":"254","author":"McCarty DJ","year":"1985","unstructured":"McCarty DJ, O\u2019Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA. 1985, 254:2763-7. 10.1001\/jama.1985.03360190069027","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001613","article-title":"Remitting seronegative symmetrical synovitis with pitting edema: a review","volume":"69","author":"Lakhmalla M","year":"2021","unstructured":"Lakhmalla M, Dahiya DS, Kichloo A, Fatima T, Edigin E, Wani F. Remitting seronegative symmetrical synovitis with pitting edema: a review. J Investig Med. 2021, 69:86-90. 10.1136\/jim-2020-001613","journal-title":"J Investig Med"},{"key":"ref8","article-title":"RS3PE revisited: a systematic review and meta-analysis of 331 cases","volume":"34","author":"Karmacharya P","year":"2016","unstructured":"Karmacharya P, Donato AA, Aryal MR, et al.. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol. 2016, 34:404-15.","journal-title":"Clin Exp Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244479","article-title":"Remitting seronegative symmetrical synovitis with pitting oedema following BNT162b2 mRNA COVID-19 vaccination","volume":"14","author":"Parperis K","year":"2021","unstructured":"Parperis K, Constantinou M. Remitting seronegative symmetrical synovitis with pitting oedema following BNT162b2 mRNA COVID-19 vaccination. BMJ Case Rep. 2021, 14:10.1136\/bcr-2021-244479","journal-title":"BMJ Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17502","article-title":"New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination","volume":"35","author":"Quattrini L","year":"2021","unstructured":"Quattrini L, Verardi L, Caldarola G, Peluso G, De Simone C, D'Agostino M. New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination. J Eur Acad Dermatol Venereol. 2021, 35:e727-9. 10.1111\/jdv.17502","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0157-2","article-title":"Remitting seronegative symmetrical synovitis pitting oedema after BCG instillation","volume":"25","author":"El Mahou S","year":"2006","unstructured":"El Mahou S, Popa L, Constantin A, et al.. Remitting seronegative symmetrical synovitis pitting oedema after BCG instillation. Clin Rheumatol. 2006, 25:566-7. 10.1007\/s10067-005-0157-2","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2002.00789.x","article-title":"Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis","volume":"38","author":"O\u011fuz F","year":"2002","unstructured":"O\u011fuz F, Akdeniz C, Un\u00fcvar E, K\u00fc\u00e7\u00fckbasmaci O, Sidal M. Parvovirus B19 in the acute arthropathies and juvenile rheumatoid arthritis. J Paediatr Child Health. 2002, 38:358-62. 10.1046\/j.1440-1754.2002.00789.x","journal-title":"J Paediatr Child Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09110-6","article-title":"Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy","volume":"349","author":"S\u00f6derlund M","year":"1997","unstructured":"S\u00f6derlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet. 1997, 349:1063-5. 10.1016\/S0140-6736(96)09110-6","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.05485-0","article-title":"Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19","volume":"53","author":"Corcoran A","year":"2004","unstructured":"Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol. 2004, 53:459-75. 10.1099\/jmm.0.05485-0","journal-title":"J Med Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.7.597","article-title":"Persistence of parvovirus B19 in synovial fluid and bone marrow","volume":"54","author":"Nikkari S","year":"1995","unstructured":"Nikkari S, Roivainen A, Hannonen P, M\u00f6tt\u00f6nen T, Luukkainen R, Yli-Jama T, Toivanen P. Persistence of parvovirus B19 in synovial fluid and bone marrow. Ann Rheum Dis. 1995, 54:597-600. 10.1136\/ard.54.7.597","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12854","article-title":"Remitting seronegative symmetrical synovitis with pitting edema associated with parvovirus B19 infection: two new cases and review of the comorbidities","volume":"54","author":"Drago F","year":"2015","unstructured":"Drago F, Ciccarese G, Agnoletti AF, Cogorno L, Muda A, Cozzani E, Parodi A. Remitting seronegative symmetrical synovitis with pitting edema associated with parvovirus B19 infection: two new cases and review of the comorbidities. Int J Dermatol. 2015, 54:e389-93. 10.1111\/ijd.12854","journal-title":"Int J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.003","article-title":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab","volume":"47","author":"Gauci ML","year":"2017","unstructured":"Gauci ML, Baroudjian B, Laly P, et al.. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Semin Arthritis Rheum. 2017, 47:281-7. 10.1016\/j.semarthrit.2017.03.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref18","article-title":"Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema","volume":"32","author":"Perandones CE","year":"2005","unstructured":"Perandones CE, Colmegna I, Arana RM. Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol. 2005, 32:389-90.","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2013.05.009","article-title":"[Reactivation of parvovirus B19 infection in an HIV-infected woman]","volume":"35","author":"Sterpu R","year":"2014","unstructured":"Sterpu R, Ichou H, Mah\u00e9 I, Mortier E. [Reactivation of parvovirus B19 infection in an HIV-infected woman]. Rev Med Interne. 2014, 35:396-8. 10.1016\/j.revmed.2013.05.009","journal-title":"Rev Med Interne"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701671044","article-title":"Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825)","volume":"48","author":"Garc\u00eda-Mu\u00f1oz R","year":"2007","unstructured":"Garc\u00eda-Mu\u00f1oz R, Galar A, Moreno C, et al.. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825). Leuk Lymphoma. 2007, 48:2461-4. 10.1080\/10428190701671044","journal-title":"Leuk Lymphoma"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086\/504812","article-title":"Parvovirus B19 infection after transplantation: a review of 98 cases","volume":"43","author":"Eid AJ","year":"2006","unstructured":"Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006, 43:40-8. 10.1086\/504812","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.08.048","article-title":"Herpes zoster after COVID vaccination","volume":"111","author":"van Dam CS","year":"2021","unstructured":"van Dam CS, Lede I, Schaar J, Al-Dulaimy M, R\u00f6sken R, Smits M. Herpes zoster after COVID vaccination. Int J Infect Dis. 2021, 111:169-71. 10.1016\/j.ijid.2021.08.048","journal-title":"Int J Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6146","article-title":"Herpes zoster following COVID-19 vaccination","volume":"20","author":"David E","year":"2021","unstructured":"David E, Landriscina A. Herpes zoster following COVID-19 vaccination. J Drugs Dermatol. 2021, 20:898-900. 10.36849\/JDD.6146","journal-title":"J Drugs Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti PM","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020, 396:467-78. 10.1016\/S0140-6736(20)31604-4","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase\u00a0I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan MJ","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, et al.. Phase\u00a0I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020, 586:589-93. 10.1038\/s41586-020-2639-4","journal-title":"Nature"},{"key":"ref26","article-title":"Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema","volume":"17","author":"Cantini F","year":"1999","unstructured":"Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol. 1999, 17:741-4.","journal-title":"Clin Exp Rheumatol"},{"key":"ref27","article-title":"Remitting seronegative symmetrical synovitis with pitting edema syndrome: follow up for neoplasia","volume":"32","author":"Rusell EB","year":"2005","unstructured":"Rusell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: follow up for neoplasia. J Rheumatol. 2005, 32:1760-1.","journal-title":"J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96833-acute-onset-of-remitting-seronegative-symmetrical-synovitis-with-pitting-edema-rs3pe-two-weeks-after-covid-19-vaccination-with-mrna-1273-with-possible-activation-of-parvovirus-b19-a-case-report-with-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:30Z","timestamp":1707507630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96833-acute-onset-of-remitting-seronegative-symmetrical-synovitis-with-pitting-edema-rs3pe-two-weeks-after-covid-19-vaccination-with-mrna-1273-with-possible-activation-of-parvovirus-b19-a-case-report-with-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.24952","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}